CMV Diverticulitis: Diagnostic Testing and Treatment
For suspected CMV diverticulitis, obtain colonoscopy with tissue biopsy for CMV-specific immunohistochemistry (the gold standard), initiate IV ganciclovir 5 mg/kg twice daily immediately upon diagnosis, add broad-spectrum antibiotics, and reserve surgery only for complications like perforation, toxic megacolon, or fulminant colitis. 1
Diagnostic Approach
Gold Standard Testing
- Tissue biopsy with CMV-specific immunohistochemistry is mandatory and represents the definitive diagnostic test 1
- Look for "owl eye" inclusion bodies on hematoxylin-eosin staining (highly specific but less sensitive than immunohistochemistry) 1
- Obtain multiple biopsies (at least 6) even from normal-appearing mucosa, as early disease may not be endoscopically apparent 1
Endoscopic Findings
- Well-defined, punched-out ulcerations present in up to 80% of cases 1
- In immunocompromised patients with graft-versus-host disease, look for typical cecum ulcers involving the ileocecal valve 1
- Friable, fungating masses may rarely occur and can mimic malignancy 2
Imaging
- Contrast-enhanced CT scan shows bowel wall thickening (almost always present) 1
- Small bowel thickening occurs in up to 40% of CMV infections (helps differentiate from C. difficile colitis where this is absent) 1
- Pancolic involvement is rare in CMV 1
Tests to AVOID or Interpret Cautiously
- Blood serology has NO diagnostic value - 70% of adults are CMV seropositive regardless of active disease 1
- Serum CMV PCR: only 61% sensitive, though 91% specific 3
- Stool CMV PCR: 53-70% sensitive, 91-92% specific 4, 3
- These noninvasive tests cannot replace colonoscopy but may help when endoscopy is contraindicated 4
Treatment Algorithm
Medical Management (First-Line)
Adults:
- IV ganciclovir 5 mg/kg twice daily for 3-5 days 1
- Transition to oral valganciclovir 900 mg twice daily to complete 2-3 week course 1
- Add broad-spectrum antibiotics (mandatory) 1
- Bowel rest 1
Pediatric patients:
- 14-21 days of parenteral ganciclovir (do NOT switch early to oral - this promotes CMV reactivation) 1
Critical Prognostic Information
- In-hospital mortality approaches 70% in severely ill immunocompetent patients despite treatment 1
- Mortality is even higher in immunocompromised patients 1
- Untreated CMV disease in immunodeficient patients carries significantly higher morbidity and mortality 1
- Patients with concurrent inflammatory bowel disease and CMV colitis have up to 7 times higher in-hospital mortality 1
Surgical Indications (Reserved for Complications Only)
Absolute indications for emergency surgery: 1
- Toxic megacolon
- Fulminant colitis
- Perforation
- Ischemia/bowel wall necrosis
Surgical approach:
- Subtotal or partial colectomy indicated 1
- No definitive data exists on superiority of segmental versus subtotal colonic resection 1
- Adopt damage control approach in severely sick patients with physiological derangement 1
Critical Pitfalls to Avoid
- Do not rely on blood serology - it cannot diagnose active CMV colitis 1
- Do not delay antiviral therapy while awaiting confirmatory testing if clinical suspicion is high and tissue diagnosis suggests CMV 5
- Do not increase immunosuppression in patients with severe colitis without ruling out CMV - this will worsen outcomes 5
- Do not switch pediatric patients to oral therapy early - this promotes viral reactivation 1
- Do not perform surgery unless complications present - medical management is first-line 1
- Consider CMV even in immunocompetent patients presenting with severe colitis, as primary CMV infection can cause life-threatening disease 6, 7
Special Populations
Immunocompromised patients (transplant recipients, HIV/AIDS, malignancy, chemotherapy):
- Higher index of suspicion required
- CMV accounts for up to 34% of severe acute colitis in this population 1
- Liver transplant recipients: 4.9% 10-year cumulative incidence of CMV end-organ disease 1
- Stem cell transplant: 15-25% incidence of CMV end-organ disease 1
Inflammatory bowel disease patients: